Akero Therapeutics Inc (AKRO)

06:27 AM

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 10,000 Shares of Stock - MarketBeat

06:27 AM

Feb 21, 2025

Akero Therapeutics chief development officer sells $498k in stock By Investing.com - Investing.com Nigeria

Feb 21, 2025

Feb 21, 2025

Akero Therapeutics chief development officer sells $498k in stock - Investing.com

Feb 21, 2025

Feb 21, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Growth in Short Interest - MarketBeat

Feb 21, 2025

Feb 20, 2025

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire

Feb 20, 2025

Feb 20, 2025

Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire

Feb 20, 2025

Feb 20, 2025

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino’s Pizza Corp. (NASDAQ: DPZ) - TradingView

Feb 20, 2025

Feb 19, 2025

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Feb 19, 2025

Feb 19, 2025

10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey

Feb 19, 2025

Feb 19, 2025

Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025 - Insider Monkey

Feb 19, 2025

Feb 19, 2025

Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN

Feb 19, 2025

Feb 17, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Average PT from Brokerages - MarketBeat

Feb 17, 2025

Feb 17, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Increase in Short Interest - Defense World

Feb 17, 2025

Feb 17, 2025

Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $75.86 - Defense World

Feb 17, 2025

Feb 16, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares - MarketBeat

Feb 16, 2025

Feb 15, 2025

(AKRO) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 15, 2025

Feb 14, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation - Markets Insider

Feb 14, 2025

Feb 13, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - Markets Insider

Feb 13, 2025

Feb 13, 2025

Is Akero Therapeutics Inc (NASDAQ: AKRO) A Good Pick For New Investors Now? - Stocks Register

Feb 13, 2025

Feb 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by abrdn plc - MarketBeat

Feb 12, 2025

Feb 12, 2025

Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock - MSN

Feb 12, 2025

Feb 12, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - Markets Insider

Feb 12, 2025

Feb 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 18,750 Shares - MarketBeat

Feb 12, 2025

Feb 12, 2025

Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing - Marketscreener.com

Feb 12, 2025

Feb 11, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Acquires 200,000 Shares - MarketBeat

Feb 11, 2025

Feb 11, 2025

Akero Therapeutics CEO Cheng Andrew Sells 30,000 Shares - TradingView

Feb 11, 2025

Feb 11, 2025

Investigation announced for Long-Term Investors in shares - openPR

Feb 11, 2025

Feb 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Feb 11, 2025

Feb 11, 2025

Financial Analysis: Akero Therapeutics Inc (AKRO)’s Ratios Unveil Key Insights - The Dwinnex

Feb 11, 2025

Feb 10, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - Markets Insider

Feb 10, 2025

Feb 10, 2025

Akero Therapeutics' chief scientific officer sells $1.06 million in stock - MSN

Feb 10, 2025

Feb 09, 2025

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider

Feb 09, 2025

Feb 09, 2025

Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - MSN

Feb 09, 2025

Feb 09, 2025

Jonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Feb 09, 2025

Feb 08, 2025

Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel

Feb 08, 2025

Feb 08, 2025

This Stock Just Doubled in 1 Day -- Is It Still a Buy? - AOL

Feb 08, 2025

Feb 08, 2025

Akero Therapeutics' chief scientific officer sells $1.06 million in stock By Investing.com - Investing.com South Africa

Feb 08, 2025

Feb 07, 2025

Akero Therapeutics’ chief scientific officer sells $1.06 million in stock By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 07, 2025

Akero Therapeutics Stock Doubles on Liver Data - MSN

Feb 07, 2025

Feb 07, 2025

Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock By Investing.com - Investing.com Australia

Feb 07, 2025

Feb 07, 2025

Akero Therapeutics' Chief Scientific Officer Sells Shares - TradingView

Feb 07, 2025